Heptares Therapeutics
Ben Jones has a work experience that includes serving as a Senior Scientist at Sosei Heptares since January 2023. Prior to that, they worked as a Postdoctoral Researcher at Colorado State University from October 2021 to November 2022, focusing on the development of methodology for the functionalisation of medicinally relevant heterocycles. Ben also had an intern experience as a Medicinal Chemistry Intern at Roche from September 2014 to August 2015.
Ben Jones holds a Master's Degree in Medicinal Chemistry MChem/BSc, which they obtained from the University of Leeds between 2012 and 2016. Ben later pursued a DPhil in Organic Chemistry at the University of Oxford from 2016 to 2021.
Heptares Therapeutics
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.